The insects would carry genetically engineered viruses that could be deployed rapidly if critical crops such as corn or wheat became vulnerable to a drought, a natural blight or a sudden attack by a biological weapon.
Japan has issued draft guidelines that allow the use of gene-editing tools in human embryos.
The potential to use gene editing in germ cells or embryos is very real.
Two papers describing anti-CRISPR proteins were supported by a Defense Advanced Research Projects Agency (DARPA) program to improve the safety of the gene-editing method and to counteract its nefarious use.
Two papers describing anti-CRISPR proteins were supported by a US Defense Advanced Research Projects Agency (DARPA) program to improve the safety of the gene-editing method and to counteract its nefarious use.
The Trump administration wants to modernize the federal guidelines for companies that sell made-to-order DNA in hopes of keeping dangerous genetic material out of the hands of malicious potential customers.
CRISPR 2018 is a continuation of the highly successful meetings previously held in Berkeley (2008-2012), Wageningen (2010), St Andrews (2013), Berlin (2014), New York (2015), Rehovot (2016), and Big Sky (2017). Traditionally these annual meetings, involving fundamental researchers, applied scientists, and industry representatives, have been critical to the progress of the exciting CRISPR-Cas field.
The 2018 conference will be the fifth meeting on Dynamic DNA Structures in Biology, a highly interactive meeting that brings together a diverse, international community of researchers who maintain a “DNA-centric” view of basic biological processes. Attendees will include those interested in disease-causing repeat expansions, chromosome fragility and rearrangements related to transcription and replication, genome editing and mutational processes, and the biological roles of unusual, non-B DNA structures.
The experiments and business activities of the biohacker community have aroused increasing attention from the US Food and Drug Administration (FDA).
Closer examination of the potential for risk should clarify how technology ought to be managed or mitigated.